KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) Return on Equity: 2011-2024

Historic Return on Equity for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to 0.08%.

  • Supernus Pharmaceuticals' Return on Equity fell 8.00% to -0.02% in Q3 2025 from the same period last year, while for Sep 2025 it was -0.02%, marking a year-over-year decrease of 8.00%. This contributed to the annual value of 0.08% for FY2024, which is 7.00% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported Return on Equity of 0.08% as of FY2024, which was up 5,084.03% from 0.00% recorded in FY2023.
  • Supernus Pharmaceuticals' Return on Equity's 5-year high stood at 0.19% during FY2020, with a 5-year trough of 0.00% in FY2023.
  • Moreover, its 3-year median value for Return on Equity was 0.07% (2022), whereas its average is 0.05%.
  • Its Return on Equity has fluctuated over the past 5 years, first decreased by 12bps in 2021, then grew by 7bps in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Return on Equity stood at 0.19% in 2020, then declined by 12bps to 0.07% in 2021, then remained steady at 0.07% in 2022, then declined by 7bps to 0.00% in 2023, then rose by 7bps to 0.08% in 2024.